Entheogens and Psychedelics including Ayahuasca, LSD, Peyote, Mescaline, Psilocybin Mushrooms, Salvia


Related Chapter:

Page last updated June 9, 2020 by Doug McVay, Editor/Senior Policy Analyst.

26. How To Use Psilocybin (Magic Mushrooms)

"Mushrooms containing psilocybin are available fresh or dried and are typically taken orally. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and its biologically active form, psilocin (4-hydroxy-N,N-dimethyltryptamine), cannot be inactivated by cooking or freezing preparations. Thus, they may also be brewed as a tea or added to other foods to mask their bitter flavor. The effects of psilocybin, which appear within 20 minutes of ingestion, last approximately 6 hours."

NIDA InfoFacts, "Hallucinogens: LSD, Peyote, Psilocybin, and PCP" National Institute on Drug Abuse (Bethesda, MD: National Institutes of Health, June 2009)

27. Physical Effects of Psilocybin

"[Psilocybin] can produce muscle relaxation or weakness, ataxia, excessive pupil dilation, nausea, vomiting, and drowsiness. Individuals who abuse psilocybin mushrooms also risk poisoning if one of many existing varieties of poisonous mushrooms is incorrectly identified as a psilocybin mushroom."

NIDA InfoFacts, "Hallucinogens: LSD, Peyote, Psilocybin, and PCP" National Institute on Drug Abuse (Bethesda, MD: National Institutes of Health, June 2009)

28. Effects of Psilocybin

"The active compounds in psilocybin-containing 'magic' mushrooms have LSD-like properties and produce alterations of autonomic function, motor reflexes, behavior, and perception.3 The psychological consequences of psilocybin use include hallucinations, an altered perception of time, and an inability to discern fantasy from reality. Panic reactions and psychosis also may occur, particularly if a user ingests a large dose. Long-term effects such as flashbacks, risk of psychiatric illness, impaired memory, and tolerance have been described in case reports."

NIDA InfoFacts, "Hallucinogens: LSD, Peyote, Psilocybin, and PCP" National Institute on Drug Abuse (Bethesda, MD: National Institutes of Health, June 2009)

29. Psilocybin and Mystical Experiences

"Overall, the present study shows that psilocybin can dose-dependently occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. The observations that episodes of extreme fear, feeling trapped, or delusions occur at the highest dose in almost 40% of volunteers, that anxiety and fear have an unpredictable time course across the session, and that an ascending sequence of dose exposure may be associated with long-lasting positive changes have implications for the design of therapeutic trials with psilocybin. Considering the rarity of spontaneous mystical experiences in the general population, the finding that more than 70% of volunteers in the current study had 'complete' mystical experiences suggests that most people have the capacity for such experiences under appropriate conditions and, therefore, such experiences are biologically normal."

Griffiths, Roland R.; Johnson, Matthew W.; Richards, William A.; Richards, Brian D.; McCann, Una; and Jesse, Robert, "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects," Psychopharmacology (Heidelberg, Germany: May 2011), p. 16.

30. Safety of Psilocybin

"An important finding of the present study is that, with careful volunteer screening and preparation and when sessions are conducted in a comfortable, well-supervised setting, a high dose of 30 mg/70 kg psilocybin can be administered safely. . It is also noteworthy that, despite meetings and prior sessions with monitors ranging from 8 h (when psilocybin was administered on the first session) up to 24 h (when psilocybin was administered on the third session) of contact time, 22% (8 of 36) of the volunteers experienced a period of notable anxiety/dysphoria during the session, sometimes including transient ideas of reference/paranoia. No volunteer required pharmacological intervention and the psychological effects were readily managed with reassurance. The primary monitor remained accessible via beeper/phone to each volunteer for 24 h after each session, but no volunteer called before the scheduled follow-up meeting on the next day. The 1-year follow-up is ongoing but has been completed by most volunteers (30 of 36). In that follow-up, an open-ended clinical interview reflecting on the study experiences and current life situation provides a clinical context conducive to the spontaneous reporting of study-associated adverse events. To date, there have been no reports of persisting perceptional phenomena sometimes attributed to hallucinogen use or of recreational abuse of hallucinogens, and all participants appear to continue to be high-functioning, productive members of society."

Griffiths, R. R.; Richards, W. A.; McCann, U.; Jesse, R., " Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance,"Psychopharmacology (Heidelberg, Germany: August 2006), Volume 187, Number 3, p. 281.